BioSpace News Archive

Pharm Country

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

March 18, 2023
·
3 min read
Drug Development

Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata

Concert Pharmaceuticals, a company recently acquired by Sun Pharmaceutical Industries Limited, announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA2.

March 18, 2023
·
8 min read
Drug Development

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

March 18, 2023
·
9 min read
Drug Development

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

Takeda announced positive results from a Phase 2b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis.

March 18, 2023
·
14 min read
BioMidwest

AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy

AbbVie announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI®, an IL-23 inhibitor.

March 18, 2023
·
13 min read
BioMidwest

Pivotal Clinical SAHARA Study Shows Candesant Biomedical’s Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Candesant Biomedical announced findings from its pivotal clinical study of its investigational sweat control patch, the first three-minute patch for the significant reduction of excessive underarm sweating in patients with primary axillary hyperhidrosis.

March 18, 2023
·
7 min read
Biotech Beach

ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa

ACELYRIN, INC. announced data from the open label Part A of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa that demonstrated treatment with izokibep led to high orders of HiSCR response at 12 weeks, including HiSCR100 responses in 33% of participants.

March 18, 2023
·
4 min read